Description
Added on the 24/11/2020 13:00:00 - Copyright : EFE Inglés
A manufacturing error is raising concerns about a promising COVID-19 vaccine being developed. The vaccine was developed by pharmaceutical company AstraZeneca and the University of Oxford. Less than a week after we learned about it, the developers have admitted to a manufacturing error. The error resulted from two different doses during the recently concluded phase III trial. AstraZeneca and the University of Oxford described the vaccine as being 70% effective. However, that number now seems a bit misleading but not necessarily in a bad way.
Tokyo, May 19 (EFE/EPA).- The Tokyo stock benchmark Nikkei briefly rose over 500 points during the trading on Tuesday due to expectation for vaccine development of the COVID-19 coronavirus, before ending at 20,433.45 points, up 299.72 points or 1.49 percent(Camera: KIMIMASA MAYAMA).FOOTAGE SHOWS PEDESTRIANS WALKING PAST A SCREEN SHOWING CLOSING INFORMATION OF TOKYO'S NIKKEI STOCK AVERAGE, WHILE THE JAPANESE CAPITAL IS STILL UNDER CORONAVIRUS STATE OF EMERGENCY, IN TOKYO, JAPAN.
The first official budget figures since Britain voted to leave the EU show a smaller-than-expected budget surplus. As post-referendum data continues to trickle in, attention is turning to what sort of access Britain will seek with its main trading partners in the EU. Kirsty Basset reports.
|
Support : Technical 
- Content 
- Editors 
